These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6815296)

  • 1. Measuring the benefits of screening for open neural tube defects.
    Henderson JB
    J Epidemiol Community Health; 1982 Sep; 36(3):214-9. PubMed ID: 6815296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An economic appraisal of the benefits of screening for open spina bifida.
    Henderson JB
    Soc Sci Med; 1982; 16(5):545-60. PubMed ID: 6808668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can we afford screening for neural tube defects? The South Wales experience.
    Hibbard BM; Roberts CJ; Elder GH; Evans KT; Laurence KM
    Br Med J (Clin Res Ed); 1985 Jan; 290(6464):293-5. PubMed ID: 3917791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When does mass screening for open neural tube defects in low-risk pregnancies result in cost savings?
    Tosi LL; Detsky AS; Roye DP; Morden ML
    CMAJ; 1987 Feb; 136(3):255-65. PubMed ID: 2433011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-benefit analysis of a population screening programme for neural tube defects.
    Sadovnick AD; Baird PA
    Prenat Diagn; 1983; 3(2):117-26. PubMed ID: 6413966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing value for money in medical screening.
    Cairns JA; Shackley P
    J Med Screen; 1994 Jan; 1(1):39-44. PubMed ID: 8790484
    [No Abstract]   [Full Text] [Related]  

  • 7. Marginal costs and benefits.
    Torgerson DJ; Spencer A
    BMJ; 1996 Jan; 312(7022):35-6. PubMed ID: 8555859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prenatal detection of open neural tube defects in a mass screening program by determination of alpha-fetoprotein concentration in maternal serum].
    Zwahr C; Körner H; Tinschert S; Horn A; Schulze M; Voigt M
    Zentralbl Gynakol; 1988; 110(3):158-67. PubMed ID: 2452529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we afford screening for neural tube defects.
    Spencer K; Carpenter P
    Br Med J (Clin Res Ed); 1985 Mar; 290(6469):711-2. PubMed ID: 2578851
    [No Abstract]   [Full Text] [Related]  

  • 10. Screening for neural tube defects.
    Scott-Samuel A
    Lancet; 1980 Mar; 1(8167):550. PubMed ID: 6102277
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevalence of neural tube defects in United States Army treatment facilities, 1975-1985; cost analysis of routine screening.
    Boling RO; Schipul AH; Barnhill DR; Chaney S; Beam TL
    Mil Med; 1988 Jun; 153(6):293-5. PubMed ID: 2455252
    [No Abstract]   [Full Text] [Related]  

  • 12. The economic perspective.
    Brown J; Buxton M
    Br Med Bull; 1998; 54(4):993-1009. PubMed ID: 10367428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prenatal screening for genetic disorders: Suggested guidelines for the Indian Scenario.
    Phadke SR; Puri RD; Ranganath P
    Indian J Med Res; 2017 Dec; 146(6):689-699. PubMed ID: 29664026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of prenatal diagnosis: methodological issues and concerns.
    Caughey AB
    Gynecol Obstet Invest; 2005; 60(1):11-8. PubMed ID: 15692215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of neural tube defects in South Australia, 1966-91: effectiveness and impact of prenatal diagnosis.
    Chan A; Robertson EF; Haan EA; Keane RJ; Ranieri E; Carney A
    BMJ; 1993 Sep; 307(6906):703-6. PubMed ID: 8401091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs and benefits of serum alpha-fetoprotein screening.
    Read AP
    Br Med J; 1978 Dec 23-30; 2(6154):1787. PubMed ID: 83895
    [No Abstract]   [Full Text] [Related]  

  • 17. [Serum analysis in pregnant women. Mass screening is an effective way to discover chromosome aberrations--arguments for and against].
    Kristoffersson U; Nørgaard-Pedersen B
    Lakartidningen; 1995 Mar; 92(12):1205-6, 1211-2. PubMed ID: 7535873
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost benefit analysis of screening spina bifida.
    Baker PA
    N Z Med J; 1981 Jun; 93(685):386-9. PubMed ID: 6166913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for neural-tube defects.
    Lancet; 1983 Jul; 2(8341):99-100. PubMed ID: 6134977
    [No Abstract]   [Full Text] [Related]  

  • 20. A cost-benefit analysis of prenatal diagnosis for neural tube defects selectively offered to relatives of index cases.
    Sadovnick AD; Baird PA
    Am J Med Genet; 1982 May; 12(1):63-73. PubMed ID: 6807091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.